In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Ltd.

www.cipla.com

Latest From Cipla Ltd.

COVID-19 Demand Gives Lupin Optimism On Albuterol

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Strategy Coronavirus COVID-19

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Coronavirus COVID-19 BioPharmaceutical

Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting

Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.

Commercial Deals

Lupin Optimistic On Albuterol Given COVID-19 Demand

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Commercial Coronavirus COVID-19
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gynecological, Urological
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Cipla Ltd.
  • Senior Management
  • Umang Vohra, Managing Dir. & Global CEO
    Kedar Upadhye, Global CFO
  • Contact Info
  • Cipla Ltd.
    Phone: (91) 22 24826000
    Peninsula Business Park
    Lower Parel
    Mumbai, 400008
    India
UsernamePublicRestriction

Register